The agreement was only for 18 months, and that was more than 18 months ago. They may have extended it, but the last comment is correct about the Biologic's team in TX losing the leader of that program. The other person leading it is in Hip Product Management. I wouldn't hold my breath for this product...hard to show value when antibiotic cement works well in knees, hard to get a regulatory claim (probably a long term clinical study), a surface treatment on a bearing surface (e.g. hip ball or distal knee condyle) will conflict with other design priorities. It will be difficult to upcharge a significant amount for this technology when the incidence rate of infection is 1-1.5% (albeit with great cost).
